Neumora Research Development from 2010 to 2026
| NMRA Stock | 3.20 0.05 1.54% |
Research Development | First Reported 2020-12-31 | Previous Quarter 38.7 M | Current Value 40.5 M | Quarterly Volatility 33.8 M |
Check Neumora Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neumora Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 557.9 K, Selling General Administrative of 37.9 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.56. Neumora financial statements analysis is a perfect complement when working with Neumora Therapeutics Valuation or Volatility modules.
Neumora | Research Development | Build AI portfolio with Neumora Stock |
Analyzing Neumora Therapeutics's Research Development over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Research Development has evolved provides context for assessing Neumora Therapeutics's current valuation and future prospects.
Latest Neumora Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of Neumora Therapeutics over the last few years. It is Neumora Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neumora Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Neumora Research Development Regression Statistics
| Arithmetic Mean | 118,544,023 | |
| Geometric Mean | 110,354,802 | |
| Coefficient Of Variation | 43.26 | |
| Mean Deviation | 42,281,562 | |
| Median | 87,126,000 | |
| Standard Deviation | 51,286,000 | |
| Sample Variance | 2630.3T | |
| Range | 143.9M | |
| R-Value | 0.73 | |
| Mean Square Error | 1299.7T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | 7,440,657 | |
| Total Sum of Squares | 42084.1T |
Neumora Research Development History
About Neumora Therapeutics Financial Statements
Neumora Therapeutics stakeholders use historical fundamental indicators, such as Neumora Therapeutics' Research Development, to determine how well the company is positioned to perform in the future. Although Neumora Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neumora Therapeutics' assets and liabilities are reflected in the revenues and expenses on Neumora Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neumora Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research Development | 231.1 M | 164.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neumora Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics Stock:Check out the analysis of Neumora Therapeutics Correlation against competitors. For information on how to trade Neumora Stock refer to our How to Trade Neumora Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics. Anticipated expansion of Neumora directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Neumora Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Neumora Therapeutics requires distinguishing between market price and book value, where the latter reflects Neumora's accounting equity. The concept of intrinsic value - what Neumora Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Neumora Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Neumora Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neumora Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neumora Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.